



CLEAN VERSION OF ALL PENDING CLAIMS

1. (Amended) A method of treating a condition which is ameliorated by inhibiting or decreasing serine protease activity of matriptase or membrane-type serine protease 1 in a mammal in need of treatment which comprises administering to said mammal a therapeutically effective amount of a compound which inhibits serine protease activity of matriptase or membrane-type serine protease 1 wherein said compound is selected from the group consisting of:


(1)




(2)



(3)




(4)




;

(5)




;

(6)




;

(7)




;

(8)




;

(9)




;

(10)



;


(11)



;


C1  
Cont

(12)




;

(13)




;

(14)



;


(15)



;


C1  
cont

(16)




;

(17)




;

(18)




;

(19)




;

(20)




;

(21)




;

(22)



; and

(23)




C1  
Cont

2. (Amended) A method according to claim 1 wherein said compound has an  $IC_{50}$  for inhibition of serine protease activity of matriptase or membrane-type serine protease 1 of 100 nM or less.


C2

4. (Amended) A method of treating a condition which is ameliorated by inhibiting or decreasing serine protease activity of matriptase or membrane-type serine protease 1 in a mammal in need of treatment which comprises administering to said mammal a therapeutically effective amount of a compound which selectively inhibits serine protease activity of matriptase or membrane-type serine protease 1 wherein said compound is selected from the group consisting of:


(1)




(2)




(3)




(4)



(5)




(6)




;

(7)



;


(8)



;


C<sup>2</sup>

(9)



;


(10)



;




(11)




;

(12)




;

(13)




;

(14)



;


(15)



;


C2  
Cont

(16)




;

(17)




;

(18)




;

(19)




;

(20)




;

(21)



;


(22)



; and


(23)

C2  
Concluded



5. (Amended) A method according to claim 4 wherein said compound has an IC<sub>50</sub> for inhibition of serine protease activity of matriptase or membrane-type serine protease 1 of 100 nM or less.

6. (Amended) The Compound of the formula:



7. (Amended) The Compound of the formula:

